Decadron (dexamethasone) / Merck (MSD) - LARVOL DELTA

The Effect of Intravenous Dexamethasone on the Duration of Peripheral Nerve Blocks in Orthopedic Surgical Adult Patients: A Systematic Review Using SWiM. (PubMed, Orthop Nurs) - "By extending the analgesic effects of peripheral nerve blocks, dexamethasone is a valuable addition to Enhanced Recovery After Surgery protocols, playing a key role in addressing the opioid epidemic."

Journal • Review • Anesthesia • Musculoskeletal Pain • Orthopedics • Pain

Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL (clinicaltrials.gov) - P2 | N=65 | Active, not recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P2 trial • Hematological Malignancies • Marginal Zone Lymphoma • Oncology • CD20

LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2027 ➔ Nov 2033 | Trial primary completion date: Mar 2027 ➔ Feb 2031

Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Myelomonocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD4 • DNMT3A • IDH1 • IDH2 • SF3B1 • SRSF2 • TET2 • U2AF1 • ZRSR2

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - P2 | N=53 | Recruiting | Sponsor: City of Hope Medical Center | Suspended ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • CD20

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - P2 | N=53 | Suspended | Sponsor: City of Hope Medical Center | Recruiting ➔ Suspended

Trial suspension • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • CD20

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov) - P3 | N=525 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: Feb 2026 ➔ Jul 2026

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

EMAT: Elimination of Minimal Residual Disease After Transplant (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Medical College of Wisconsin | Recruiting ➔ Active, not recruiting

Enrollment closed • Minimal residual disease • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (clinicaltrials.gov) - P1/2 | N=162 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

IRST185.04: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) (clinicaltrialsregister.eu) - P1/2 | N=70 | Active, not recruiting | Sponsor: Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. | Recruiting ➔ Active, not recruiting

Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=97 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • Transplantation • ABL1 • ANPEP • BCR • CD22 • CD5 • CD7 • CD79A • MME • MPO

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=464 | Recruiting | Sponsor: Celgene | Trial completion date: May 2027 ➔ Oct 2027

Monotherapy • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=106 | Not yet recruiting | Sponsor: Celgene Corporation | Trial primary completion date: Aug 2018 ➔ Apr 2020

Monotherapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=118 | Recruiting | Sponsor: Celgene | Trial primary completion date: Aug 2018 ➔ Jul 2020

Monotherapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=106 | Recruiting | Sponsor: Celgene Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=464 | Recruiting | Sponsor: Celgene | Trial completion date: Oct 2027 ➔ Feb 2028 | Trial primary completion date: Aug 2021 ➔ Apr 2022

Monotherapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=154 | Recruiting | Sponsor: Celgene | Phase classification: P1/2 ➔ P1b/2a | N=118 ➔ 154 | Trial completion date: May 2022 ➔ Jan 2023 | Trial primary completion date: Jul 2020 ➔ Mar 2021

Enrollment change • Monotherapy • Phase classification • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=118 | Recruiting | Sponsor: Celgene | Trial primary completion date: Mar 2018 ➔ Aug 2018

Monotherapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=449 | Recruiting | Sponsor: Celgene | Trial completion date: Feb 2028 ➔ Oct 2029

Monotherapy • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=532 | Active, not recruiting | Sponsor: Celgene | Phase classification: P1b/2a ➔ P1/2 | Trial completion date: Oct 2029 ➔ Feb 2028 | Trial primary completion date: Oct 2029 ➔ Mar 2024

Monotherapy • Phase classification • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=449 | Active, not recruiting | Sponsor: Celgene | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=532 | Recruiting | Sponsor: Celgene | Trial primary completion date: Apr 2022 ➔ Apr 2026

Monotherapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=303 | Recruiting | Sponsor: Celgene | N=154 ➔ 303 | Trial completion date: Jan 2023 ➔ Feb 2026

Enrollment change • Monotherapy • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=449 | Recruiting | Sponsor: Celgene | N=303 ➔ 449 | Trial primary completion date: Apr 2021 ➔ Jul 2024

Enrollment change • Monotherapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - P1b/2a | N=449 | Recruiting | Sponsor: Celgene | Trial completion date: May 2026 ➔ May 2027 | Trial primary completion date: Jul 2024 ➔ Jun 2021

Monotherapy • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

LINKER-MM8: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov) - P2/3 | N=1570 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P2/3 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation